These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37743233)

  • 1. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
    Mazzaschi G; Lazzarin A; Santoni M; Trentini F; Giorgi U; Brighi N; Tommasi C; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Silini EM; Rescigno P; Rebuzzi SE; Fornarini G; Quaini F; Giudice GC; Banna GL; Buti S
    Front Biosci (Elite Ed); 2023 Jul; 15(3):20. PubMed ID: 37743233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.
    Tommasi C; Scartabellati G; Giannarelli D; Giorgi U; Brighi N; Fornarini G; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Brunelli M; Buti S
    Ther Adv Urol; 2023; 15():17562872231187216. PubMed ID: 37492625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
    Maffezzoli M; Santoni M; Mazzaschi G; Rodella S; Lai E; Maruzzo M; Basso U; Bimbatti D; Iacovelli R; Anghelone A; Fiala O; Rebuzzi SE; Fornarini G; Lolli C; Massari F; Rosellini M; Mollica V; Nasso C; Acunzo A; Silini EM; Quaini F; De Filippo M; Brunelli M; Banna GL; Rescigno P; Signori A; Buti S
    Clin Exp Metastasis; 2024 Apr; 41(2):117-129. PubMed ID: 38363410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
    Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Karaağaç M; Artaç M
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
    Corianò M; Giannarelli D; Scartabellati G; De Giorgi U; Brighi N; Fornarini G; Tommasi C; Giudice GC; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Brunelli M; Signori A; Banna GL; Buti S
    Expert Rev Anticancer Ther; 2023 May; 23(5):545-554. PubMed ID: 37017710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
    Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
    Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib.
    Bolzacchini E; Giordano M; Bertù L; Bregni M; Nigro O; Galli L; Antonuzzo A; Artale S; Barzaghi S; Danova M; Torchio M; Pinotti G; Dentali F
    Tumori; 2022 Oct; 108(5):502-509. PubMed ID: 34296630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy.
    Aktepe OH; Guven DC; Sahin TK; Yildirim HC; Celikten B; Yeter HH; Yuce D; Dizdar O; Erman M
    Nutr Cancer; 2021; 73(10):1957-1963. PubMed ID: 33491495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.
    Anpalakhan S; Banna GL; Rebuzzi SE; Fornarini G; Maruzzo M; Zucali PA; Catalano F; Antonj L; Tudini M; Fratino L; Malgeri A; Rescigno P; Signori A; Acunzo A; Silini EM; Mazzaschi G; Buti S
    Immunotherapy; 2024; 16(14-15):963-973. PubMed ID: 39105621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
    Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
    Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
    Buti S; Tommasi C; Scartabellati G; De Giorgi U; Brighi N; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; de Filippo M; Cortellini A; Bersanelli M
    Anticancer Drugs; 2023 Jan; 34(1):178-186. PubMed ID: 36539370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative red blood cell distribution width as an independent prognostic factor in metastatic renal cell carcinoma.
    Wei Z; Zhang F; Ma X; He W; Gou X; Zhang X; Xie Y
    Transl Oncol; 2022 Sep; 23():101486. PubMed ID: 35839619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
    Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
    Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
    Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
    McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
    Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.